linjc16/ctgov huggingface dataset:
The Fate Of Calf Perforators After Endovenous Laser Ablation Of Saphenous Veins

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the morphologic and hemodynamic changes in the calf perforators after endovenous laser ablation of saphenous veins.

Official Title
-----------------
The Fate Of Calf Perforators After Endovenous Laser Ablation Of Saphenous Veins

Conditions
-----------------
Venous Insufficiency

Intervention / Treatment
-----------------
* Procedure: Endovenous laser ablation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Symptomatic patients who undergo EVLA procedure for saphenous vein insufficiency Exclusion Criteria: Patients with a history of deep venous thrombosis (DVT) Previous varicose vein surgery or injection sclerotherapy Patients without superficial venous incompetency

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Endovenous laser ablation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Sonographic Assessment of Fetal Deglutition Associated With Hydramnion:Its Absence is Indicative of Central Nervous System (CNS) Pathology

Study Overview
=================
Brief Summary
-----------------
310 singleton pregnancies (22-35 weeks) enrolled into the study. We assessed sonographically the fetal larynx in an axial plane through the mandible and observed the fetal deglutition movements .

Detailed Description
-----------------
310 singleton pregnancies (22-35 weeks) enrolled into the study. We assessed sonographically the fetal larynx in an axial plane through the mandible and observed the fetal deglutition movements .We encountered two cases of hydramnios were no deglutition movements could be noted. In all other cases the deglutition was normal. The motivation to conduct the current observational prospective study was to assess whether there is a link between absence of fetal deglutition and CNS pathology of the fetus. In the first case the fetus deceased at 35 weeks of gestation; obduction was declined by the parents. In the second case caesarian section at 33 weeks was carried out recently due to fetal distress. The infant is still in uncapable of swallowing and there for is under investigation at the neonatal center of our hospital.

Official Title
-----------------
Sonographic Assessment of Fetal Deglutition Associated With Hydramnion:Its Absence is Indicative of CNS Pathology? a Report on Two Cases.

Conditions
-----------------
Hydramnios

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: singleton pregnancy(22-35 weeks) Exclusion Criteria: positive toxoplasmosis screening,drug and/or antidepressants addiction.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>hydramnios | |
| 2<br>normal | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fetal deglutition, larynx, fetal CNS pathology, sonography, hydramnios
Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether aerosolized vancomycin is effective in the treatment of methicillin-resistant staphylococcus aureus pneumonia under mechanical ventilation.

Official Title
-----------------
Optimal Two-Stage Phase 2 Study of Efficacy and Pharmacokinetics of Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation

Conditions
-----------------
Pneumonia, Staphylococcal, Methicillin-Resistant Staphylococcus Aureus

Intervention / Treatment
-----------------
* Drug: Vancomycin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Nosocomial or severe community-acquired pneumonia due to Methicillin-Resistant Staphylococcus aureus Must be mechanically ventilated in intensive care unit Exclusion Criteria: Non-bacterial pneumonia, such as viral, fungal, tuberculosis infections Underlying respiratory condition: bronchiectasis, post-tuberculosis, chronic obstructive pulmonary disease or asthma Complicated pneumonia, such as empyema, parapneumonic effusion requiring chest tube or drainage Already or previous treated with intravenous vancomycin (Not pneumonia) Adverse reaction due to inhaled ventolin before treatment of aerosolized vancomycin Hypersensitivity of vancomycin or glycopeptide antibiotics Positive culture of Enterococcus in respiratory specimen Pregnant or Breast-feeding patient Immunocompromised hosts: more than 1mg/kg of corticosteroid users for more than 3 months, transplantation recipients, AIDS patients Another aerosolized antibiotics within 48 hours of study enrollment Not adherent to mechanical ventilation protocol of this study Not arterial line monitoring Vancomycin minimum inhibitory concentration >= 2㎍/㎖ of cultured Staphylococcus aureus

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Aerosolized Vancomycin<br> | Drug: Vancomycin<br> <br> * Other names: 250mg bid, Inhalation for 5-7 days;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical cure rate |  | within the first 30 days after treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the peak level of serum vancomycin level |  | on 3rd and 5th days after treatment |
Subcutaneous Suppressive Antibiotic Therapy for Bone and Joint Infections

Study Overview
=================
Brief Summary
-----------------
For patients having a bone or joint infections, with or without device, optimal surgical therapy could be sometimes non-feasible, especially in the elderly population. Therefore, a medical therapy with oral prolonged suppressive antibiotic therapy (PSAT) seems to be an option to prevent recurrence and prosthesis loosening. Subcutaneous (SC) administration of injectable intravenous antibiotics as prolonged suppressive antibiotic therapy could be a convenient way when oral treatment is not available to facilitate ambulatory care, this practice being considered as routine care. The aim of this study is to evaluate tolerance and efficacy of subcutaneous administration of antibiotics for prolonged suppressive antibiotic therapy in patients having this treatment as part of their routine care.

Official Title
-----------------
Subcutaneous Suppressive Antibiotic Therapy for Bone and Joint Infections

Conditions
-----------------
Bone Infection, Joint Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients having bone or joint infection, patients with or without device treated by sub-cutaneous prolonged antibiotic therapy Exclusion Criteria: diabetic foot osteomyelitis pressure ulcer-associated osteomyelitis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Description of sub-cutaneous administration of antibiotics for PSAT | In case of PSAT (prolonged suppressive antibiotic therapy), the duration could be several years. The data collected are: name of molecule, rough, posology, duration. | 60 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tolerance of sub-cutaneous administration of antibiotics for PSAT | In case of PSAT (prolonged suppressive antibiotic therapy), the duration could be several years. This outcome will focus on severe adverse events induced by this sub-cutaneous and prolonged antibiotic therapy. Qualification of an adverse event is made using the CTCAE terminology: this terminology attributes a grade for every adverse event. There are 5 grades and a grade refers to the severity of the adverse event. A severe adverse event has a grade >=3. | 60 months | 
| Efficacy of sub-cutaneous administration of antibiotics for PSAT | A treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin. | 60 months |
Precision Orthodontics: A Comparison of Custom vs Traditional Bracket Treatment Efficiency

Study Overview
=================
Brief Summary
-----------------
This investigational testing aims to target multiple investigations sites to examine treatment efficiency metrics using a completely digital and patient-specific bracket treatment system for the correction of malocclusions.

Official Title
-----------------
Precision Orthodontics: A Comparison of Custom vs Traditional Bracket Treatment Efficiency

Conditions
-----------------
Dental Malocclusion

Intervention / Treatment
-----------------
* Device: LightForce Orthodontic System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All subjects must be healthy and between the ages of 10 and 65. Eruption of all permanent teeth excluding second and third molars Sufficient labial tooth surface for bonding No more than one tooth missing from a single arch quadrant No existing molar tubes or bands Exclusion Criteria: Presence of systemic diseases, cleft lip and palate, craniofacial anomalies, syndromes affecting bone or teeth, impacted teeth (excluding 3rd molars), and tumors of the parathyroid gland Presence of bridges or implants Cases requiring orthognathic surgery Significant periodontal disease Intake of drugs affecting tooth movement or bone formation (chronic use of Non-Steroidal Anti-Inflammatory Drugs, bisphosphonates, levothyroxine, or teriparatide drug class) Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients with Malocclusion<br> | Device: LightForce Orthodontic System<br>* The LightForce Orthodontic System is a a digital treatment planning platform and patient-specific 3D printed polycrystalline alumina brackets for the treatment of malocclusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of treatment |  | approximately 2 years | 
| Length of bonding appointment |  | 1 day | 
| Length of debonding appointment |  | approximately 2 years | 
| Length of time to achieve leveling and aligning |  | approximately 1 years | 
| number of unscheduled appointment |  | approximately 2 years | 
| number of debonded brackets |  | approximately 2 years | 
| number of repositioned brackets |  | approximately 2 years |
Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and efficacy of Domestic Tenofovir Disoproxil Fumarate Tablets in Chinese patients with hepatitis B ,compared with Tenofovir Disoproxil Fumarate Tablets of Gilead.

Conditions
-----------------
Chronic Hepatitis B

Intervention / Treatment
-----------------
* Drug: Domestic Tenofovir Disoproxil Fumarate Tablets
* Drug: Tenofovir Disoproxil Fumarate Tablets of Gilead


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The initial treatment of subjects diagnosed of HBeAg positive or negative chronic hepatitis B Aged 18 to 65 years old，male or female Patients with previously HBsAg-positive lasted for 6months at least：HBeAg-positive subjects, HBV-DNA> 105copies/ml； HBeAg-negative subjects, HBV-DNA> 104copies/ml. 2 times the upper normal limit (2 × ULN) ≤ alanine aminotransferase (ALT) ≤ 10 × ULN. Total serum bilirubin (TBIL) ≤ 2.5 × ULN. Prothrombin activity (PTA) ≥ 60% or prothrombin time prolonged than normal ≤ 3 seconds). WBC ≥ 3.5 × 109 / L, PLT ≥ 80 × 109 / L, serum albumin (ALB)≥ 35 g / L. Creatinine (Cr) ≤ 1× ULN，serum phosphate was normal. Patients signed an informed consent form and compliance was good. Exclusion Criteria: Patients were infected with other viruses as HAV, HCV, HEV, HIV etc. Patients with cirrhosis or liver cancer. Pregnant woman, lactating women . Patients with severe heart, kidney, endocrine hematopoietic system and neuropsychiatric diseases. Patients with metabolic or autoimmune diseases such as systemic lupus erythematosus. Patients allergic for study drug.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Domestic Tenofovir Disoproxil Fumarate Tablets<br> | Drug: Domestic Tenofovir Disoproxil Fumarate Tablets<br>* 1 Domestic Tenofovir Disoproxil Fumarate Tablets and 1 blank Tenofovir Disoproxil Fumarate Tablets of Gilead<br>|
| Active Comparator: Tenofovir Disoproxil Fumarate Tablets of Gilead<br> | Drug: Tenofovir Disoproxil Fumarate Tablets of Gilead<br>* 1 blank Domestic Tenofovir Disoproxil Fumarate Tablets and 1Tenofovir Disoproxil Fumarate Tablets of Gilead<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compared with baseline, decline of serum HBV-DNA in the value |  | 48 week |
Efficacy of Albendazole to Treat Intestinal Helminths and Its Effect on Gut Microflora

Study Overview
=================
Brief Summary
-----------------
Albendazole is a main anti-helminth, however there is a lack of data regarding its efficacy in the school children population. The aim of this study is to evaluate the efficacy of the albendazole one versus two and three doses, in school children infected with intestinal helminth.

Official Title
-----------------
Effect of Intestinal Helminths on Gut Microflora

Conditions
-----------------
Intestinal Diseases, Helminthiasis

Intervention / Treatment
-----------------
* Drug: albendazole
* Drug: albendazole
* Drug: albendazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: presence of intestinal helminths eggs in the stool Exclusion Criteria: allergy to imidazole derivate No intestinal helminths

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1 dose, Albendazole , tablet<br> | Drug: albendazole<br>* single 1 tablet of 400 mg of albendazole<br>|
| Active Comparator: 2 doses, albendazole, tablet<br>1 tablet of 400 mg of albendazole per day for two consecutive days | Drug: albendazole<br>* 1 tablet of 400 mg of albendazole per day for two consecutive days<br>|
| Active Comparator: 3 doses albendazole, 400mg, tablet<br> | Drug: albendazole<br>* 1 tablet of 400 mg of albendazole per day for three consecutive days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| parasite cleared and reduced up to 80% at day 42 |  | 42 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of major gut bacteria | Change in the prevalence of major gut bacteria after antihelminth treatment. | 42 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
albendazole, ascaris, trichiurus, hookworms
Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients

Study Overview
=================
Brief Summary
-----------------
The proposed project will pilot incorporation of rapid serial measurements of IP-10 into a CDS tool for moderate and severe COVID-19 patients. The tool was applied to all comers with confirmed COVID-19 diagnosis at a secondary medical center in Israel.

Official Title
-----------------
Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Diagnostic Test: IP-10 in CDS protocol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PCR- positive for COVID-19 Exclusion Criteria: <18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: IP-10 in CDS protocol|Dynamic IP-10 measurements in hospitalized COVID-19 positive patients|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IP-10 levels |  | up to 24 months |
Arterial pH Selectively Predicts Intensive Care Unit Transfer From the Emergency Department in Obese Patients With Acute Dyspnea

Study Overview
=================
Brief Summary
-----------------
This study evaluates the prognostic value of arterial blood gas analysis in a cohort of Emergency Department patients presenting with shortness of breath of any cause, comparing obese and non-obese patients.

Detailed Description
-----------------
Factors associated with admission to intensive care unit (ICU) or ED mortality before transfer to the ICU are analyzed in obese (BMI ≥ 30kg.m-2) and non-obese patients subgroups.

Official Title
-----------------
Arterial pH Selectively Predicts ICU Transfer in Obese Patients With Acute Dyspnea Presenting to the Emergency Department: a Prospective Comparative Cohort Study

Conditions
-----------------
Dyspnea, Respiratory Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who presented with acute dyspnea in the ED patients who had an ABG analysis as part of the ED standard management Exclusion Criteria: Patients with treatment limitation decisions made by the medical teams against ICU admission, including severe cognitive impairment or palliative care , Patients with immediate transfer to ICU due to shock and hemodynamic instability at ED admission

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite of admission to the ICU or in ED mortality before ICU admission | Admission to the ICU following ED management will be at the discretion of the attending ICU physician, and in agreement with current guidelines for ICU admission, according to standard management | up to 1 day (direct admission to ICU from ED) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dyspnea, pH, blood gas analysis, emergency department, Intensive care unit
Transcranial Magnetic Stimulation in Depression

Study Overview
=================
Brief Summary
-----------------
The study examines efficacy of repetitive transcranial magnetic stimulation in treating severely depressed patients who are medicated.

Detailed Description
-----------------
Medicated, treatment resistant, depressed patients are randomized to active or sham repetitive transcranial magnetic stimulation (rTMS). Responding patients go into a six months follow-up period.

Official Title
-----------------
Efficacy of Threshold vs. Subthreshold TMS in the Treatment of Depression

Conditions
-----------------
Depression

Intervention / Treatment
-----------------
* Device: repetitive transcranial magnetic stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
severe treatment-resistant depression

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: repetitive transcranial magnetic stimulation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |